Post by Warwick on Feb 20, 2019 2:01:43 GMT
Neuropozyne
Neuropozyne, informally called No-Poz or Nu-Poz, is a drug used by the mechanically augmented in the 2020s. It helps prevent neuroprosthesis rejection syndrome, a build-up of scar tissue that blocks electrical signals between augmentation electrodes and human tissue, ultimately resulting in rejection. It was created by Darrow Industries and is now manufactured exclusively by VersaLife. Unlike simple non-cybernetic implants, like a hip replacement which can be made from hypoallergenic materials, there is a need for any cybernetic augmentation that will "feel" and can be moved by the mind to have a neuroprosthetic junction, in essence a chip located within the brain to act as the interface between body and machine. Darrow Industries pioneered the PEDOT-cluster array design which was constructed to include both the organic conducting polymer electrodes and the neurons which would interface with the host's neurons, hence why it is called a "biochip".
The problem with implanting the biochip is that it causes glial tissue to build up around the junction, causing what is best described as nerve scars. The scarring eventually disrupts the integrity of the neuroprosthetic junction causing a rejection syndrome known as Darrow Deficiency Syndrome (DDS).
Neuropozyne is a compound that prevents the buildup of glial nerve tissue around the junction. It is available by prescription only and weekly doses are required to prevent the disruption of the junction. Although it is not produced with especially rare materials, its distribution is heavily monitored and it can sell for extraordinary prices on the black market. In 2027, there is a shortage of Neuropozyne. VersaLife claims that this is due to various setbacks it has experienced.
Neuropozyne, informally called No-Poz or Nu-Poz, is a drug used by the mechanically augmented in the 2020s. It helps prevent neuroprosthesis rejection syndrome, a build-up of scar tissue that blocks electrical signals between augmentation electrodes and human tissue, ultimately resulting in rejection. It was created by Darrow Industries and is now manufactured exclusively by VersaLife. Unlike simple non-cybernetic implants, like a hip replacement which can be made from hypoallergenic materials, there is a need for any cybernetic augmentation that will "feel" and can be moved by the mind to have a neuroprosthetic junction, in essence a chip located within the brain to act as the interface between body and machine. Darrow Industries pioneered the PEDOT-cluster array design which was constructed to include both the organic conducting polymer electrodes and the neurons which would interface with the host's neurons, hence why it is called a "biochip".
The problem with implanting the biochip is that it causes glial tissue to build up around the junction, causing what is best described as nerve scars. The scarring eventually disrupts the integrity of the neuroprosthetic junction causing a rejection syndrome known as Darrow Deficiency Syndrome (DDS).
Neuropozyne is a compound that prevents the buildup of glial nerve tissue around the junction. It is available by prescription only and weekly doses are required to prevent the disruption of the junction. Although it is not produced with especially rare materials, its distribution is heavily monitored and it can sell for extraordinary prices on the black market. In 2027, there is a shortage of Neuropozyne. VersaLife claims that this is due to various setbacks it has experienced.